Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients
Open Access
- 13 July 2018
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 29 (9) , 2003-2009
Abstract
New molecular biomarkers for prostate cancer (PC) prognosis are urgently needed. Ratio-based models are attractive, as they require no additional normalization. Here, we train and independently validate a novel 4-miRNA prognostic ratio model for PC. By genome-wide miRNA expression profiling of PC tissue samples from 123 men who underwent radical prostatectomy (RP) (PCA123, training cohort), we identified six top candidate prognostic miRNAs and systematically tested their ability to predict postoperative biochemical recurrence (BCR). The best miRNA-based prognostic ratio model (MiCaP) was validated in two independent cohorts (PCA352 and PCA476) including >800 RP patients in total. Clinical end points were BCR and prostate cancer-specific survival (CSS). The prognostic potential of MiCaP was assessed by univariate and multivariate Cox-regression analyses and Kaplan–Meier analyses. We identified a 4-miRNA ratio model, MiCaP (miR-23a-3p×miR-10b-5p)/(miR-133a×miR-374b-5p), that predicted time to BCR independently of routine clinicopathologic variables in the training cohort (PCA123) and was successfully validated in two independent RP cohorts. In addition, MiCaP was a significant predictor of CSS in univariate analysis [HR 3.35 (95% CI 1.34 − 8.35), P = 0.0096] and in multivariate analysis [HR 2.43 (95% CI 1.45–4.07), P = 0.0210]. As proof-of-principle, we also analyzed MiCaP in plasma samples from 111 RP patients. A high MiCaP score in plasma was significantly associated with BCR (P = 0.0036, Kaplan–Meier analysis). Limitations include low mortality rates (CSS: 5.4%). We identified a novel 4-miRNA ratio model (MiCaP) with significant independent prognostic value in three RP cohorts, indicating promising potential to improve PC risk stratification.Keywords
Funding Information
- nnovation Fund Denmark
- The Danish Cancer Society, and The Velux Foundation
- Innovation Fund Denmark (068-2012-3)
- The Danish Cancer Society (R79-A5293-13-S19, R99-A6338-14-S25)
- Velux Foundation/Velux Fonden (00011307)
This publication has 24 references indexed in Scilit:
- Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patientsBMC Genomics, 2013
- microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptorOncology Reports, 2012
- Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancerBritish Journal of Cancer, 2011
- Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancerOncogene, 2011
- miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progressionInternational Journal of Oncology, 2011
- The CAPRA‐S scoreCancer, 2011
- Treatment of localized prostate cancer: when is active surveillance appropriate?Nature Reviews Clinical Oncology, 2010
- Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005JNCI: Journal of the National Cancer Institute, 2009
- MicroRNA profile analysis of human prostate cancersCancer Gene Therapy, 2008
- EAU Guidelines on Prostate CancerEuropean Urology, 2008